HRP20110360T1 - Kombinacija zd6474 i pemetrekseda - Google Patents

Kombinacija zd6474 i pemetrekseda Download PDF

Info

Publication number
HRP20110360T1
HRP20110360T1 HR20110360T HRP20110360T HRP20110360T1 HR P20110360 T1 HRP20110360 T1 HR P20110360T1 HR 20110360 T HR20110360 T HR 20110360T HR P20110360 T HRP20110360 T HR P20110360T HR P20110360 T1 HRP20110360 T1 HR P20110360T1
Authority
HR
Croatia
Prior art keywords
pemetrexed
pharmaceutically acceptable
warm
acceptable salt
blooded animal
Prior art date
Application number
HR20110360T
Other languages
English (en)
Croatian (hr)
Inventor
Robert Wedge Stephen
Joseph Ryan Anderson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0526121A external-priority patent/GB0526121D0/en
Priority claimed from GB0610706A external-priority patent/GB0610706D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HRP20110360T1 publication Critical patent/HRP20110360T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
HR20110360T 2005-12-22 2006-12-19 Kombinacija zd6474 i pemetrekseda HRP20110360T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0526121A GB0526121D0 (en) 2005-12-22 2005-12-22 Combination therapy
GB0610706A GB0610706D0 (en) 2006-05-31 2006-05-31 Combination therapy
PCT/GB2006/004750 WO2007071958A2 (en) 2005-12-22 2006-12-19 Combination of zd6474 and pemetrexed

Publications (1)

Publication Number Publication Date
HRP20110360T1 true HRP20110360T1 (hr) 2011-06-30

Family

ID=37814151

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110360T HRP20110360T1 (hr) 2005-12-22 2006-12-19 Kombinacija zd6474 i pemetrekseda

Country Status (19)

Country Link
US (2) US20080269261A1 (pt)
EP (1) EP1971338B8 (pt)
JP (1) JP5167144B2 (pt)
KR (1) KR20080079675A (pt)
AT (1) ATE500832T1 (pt)
AU (1) AU2006328189B2 (pt)
BR (1) BRPI0620140A2 (pt)
CA (1) CA2631764A1 (pt)
CY (1) CY1111547T1 (pt)
DE (1) DE602006020621D1 (pt)
DK (1) DK1971338T3 (pt)
HR (1) HRP20110360T1 (pt)
IL (1) IL191796A0 (pt)
NO (1) NO20082567L (pt)
NZ (1) NZ568811A (pt)
PL (1) PL1971338T3 (pt)
PT (1) PT1971338E (pt)
SI (1) SI1971338T1 (pt)
WO (1) WO2007071958A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
PT1592423E (pt) * 2003-02-13 2011-06-16 Astrazeneca Ab Terapia de combinação de zd6474 com 5-fu e/ou cpt-11
EP1648465B1 (en) * 2003-07-10 2010-08-25 AstraZeneca AB Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
GB0318422D0 (en) * 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
WO2007071958A2 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of zd6474 and pemetrexed
ATE502641T1 (de) * 2005-12-22 2011-04-15 Astrazeneca Ab Kombination aus azd2171 und pemetrexed
EP2066353B1 (en) * 2006-09-29 2013-01-02 AstraZeneca AB Combination of zd6474 and bevacizumab for cancer therapy
US20090221615A1 (en) * 2008-02-29 2009-09-03 Guru Reddy Combination anti-cancer agents
BR112012022243A8 (pt) 2010-03-08 2021-11-09 Spectrum Pharmaceuticals Inc Uso de um inibidor de autofagia baseado em tioxantona e de um composto indutor de autofagia para terapia de câncer, composição farmacêutica e kit farmacêutico

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4713698B2 (ja) * 1997-03-05 2011-06-29 スージェン， インク． 疎水性薬剤の処方
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
US7001911B2 (en) * 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
AU2001292548B2 (en) * 2000-07-28 2005-06-16 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
KR20050056190A (ko) * 2002-08-09 2005-06-14 아스트라제네카 아베 암의 치료에서의 방사선 요법과 함께 혈관 내피 성장 인자수용체의 억제제인 ｚｄ6474의 병행 치료
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
PT1592423E (pt) * 2003-02-13 2011-06-16 Astrazeneca Ab Terapia de combinação de zd6474 com 5-fu e/ou cpt-11
EP1648465B1 (en) * 2003-07-10 2010-08-25 AstraZeneca AB Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
WO2007071958A2 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of zd6474 and pemetrexed
ATE502641T1 (de) * 2005-12-22 2011-04-15 Astrazeneca Ab Kombination aus azd2171 und pemetrexed
EP2066353B1 (en) * 2006-09-29 2013-01-02 AstraZeneca AB Combination of zd6474 and bevacizumab for cancer therapy

Also Published As

Publication number Publication date
BRPI0620140A2 (pt) 2011-11-01
DE602006020621D1 (de) 2011-04-21
JP2009520783A (ja) 2009-05-28
SI1971338T1 (sl) 2011-06-30
NZ568811A (en) 2011-06-30
HK1123186A1 (en) 2009-06-12
US20110212978A1 (en) 2011-09-01
CY1111547T1 (el) 2015-08-05
WO2007071958A3 (en) 2008-03-27
EP1971338B1 (en) 2011-03-09
PL1971338T3 (pl) 2011-07-29
AU2006328189A1 (en) 2007-06-28
US20080269261A1 (en) 2008-10-30
DK1971338T3 (da) 2011-05-23
IL191796A0 (en) 2008-12-29
ATE500832T1 (de) 2011-03-15
JP5167144B2 (ja) 2013-03-21
EP1971338A2 (en) 2008-09-24
EP1971338B8 (en) 2011-09-21
AU2006328189B2 (en) 2010-01-21
PT1971338E (pt) 2011-05-09
CA2631764A1 (en) 2007-06-28
NO20082567L (no) 2008-07-31
WO2007071958A2 (en) 2007-06-28
KR20080079675A (ko) 2008-09-01

Similar Documents

Publication Publication Date Title
JP2006504723A5 (pt)
MY206578A (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
HRP20110360T1 (hr) Kombinacija zd6474 i pemetrekseda
MX2021007833A (es) Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer.
MY199967A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
CL2008001932A1 (es) Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer.
ECSP109935A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
WO2016133903A3 (en) Combination therapy for cancer treatment
NZ543661A (en) Pyrazolo-quinazoline derivatives having antitumor activity and process for their preparation
PH12015501067A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
EA201200560A1 (ru) Специфическая терапия, использующая интегриновые лиганды для лечения рака
BRPI0916356A2 (pt)
DK1551409T3 (da) Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer
DE602006014579D1 (de) Heteroalkylgebundene pyrimidinderivate
TW200744602A (en) Administration of dipeptidyl peptidase inhibitors
JP2006500346A5 (pt)
TW200700093A (en) Pharmaceutical composition for the treatment of cancer
IL151628A0 (en) Combination therapies with vascular damaging activity
JP2008514577A5 (pt)
HRP20110365T1 (hr) Kombinacija azd2171 i pemetrekseda
CA2514227A1 (en) Combination therapy of zd6474 with 5-fu or/and cpt-11
JP2005530735A5 (pt)
DE60311788D1 (de) Kombinationstherapie zur behandlung von krebs
MXPA05013827A (es) Composiciones que comprenden zd6126 junto con 5-fu, cpt-11 o 5-fu y cpt-11, que tienen actividad de dano vascular, para tratar cancer colorectal e. g.